JP2012506911A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012506911A5 JP2012506911A5 JP2011534697A JP2011534697A JP2012506911A5 JP 2012506911 A5 JP2012506911 A5 JP 2012506911A5 JP 2011534697 A JP2011534697 A JP 2011534697A JP 2011534697 A JP2011534697 A JP 2011534697A JP 2012506911 A5 JP2012506911 A5 JP 2012506911A5
- Authority
- JP
- Japan
- Prior art keywords
- controlled release
- release formulation
- diacerein
- formulation
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 34
- 238000009472 formulation Methods 0.000 claims 33
- 238000013270 controlled release Methods 0.000 claims 22
- TYNLGDBUJLVSMA-UHFFFAOYSA-N 4,5-diacetyloxy-9,10-dioxo-2-anthracenecarboxylic acid Chemical compound O=C1C2=CC(C(O)=O)=CC(OC(C)=O)=C2C(=O)C2=C1C=CC=C2OC(=O)C TYNLGDBUJLVSMA-UHFFFAOYSA-N 0.000 claims 15
- 229960004590 diacerein Drugs 0.000 claims 15
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 5
- 229930195725 Mannitol Natural products 0.000 claims 5
- 239000000594 mannitol Substances 0.000 claims 5
- 235000010355 mannitol Nutrition 0.000 claims 5
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 4
- 230000036470 plasma concentration Effects 0.000 claims 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 4
- 229940069328 povidone Drugs 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 3
- 235000019359 magnesium stearate Nutrition 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 2
- 239000005541 ACE inhibitor Substances 0.000 claims 1
- 102000008873 Angiotensin II receptor Human genes 0.000 claims 1
- 108050000824 Angiotensin II receptor Proteins 0.000 claims 1
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 claims 1
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 claims 1
- 229920000858 Cyclodextrin Polymers 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 208000003790 Foot Ulcer Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 206010040943 Skin Ulcer Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 239000002535 acidifier Substances 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 239000003405 delayed action preparation Substances 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 229940126904 hypoglycaemic agent Drugs 0.000 claims 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 230000003204 osmotic effect Effects 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000003087 receptor blocking agent Substances 0.000 claims 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10893108P | 2008-10-28 | 2008-10-28 | |
| US61/108,931 | 2008-10-28 | ||
| PCT/US2009/062302 WO2010051296A1 (en) | 2008-10-28 | 2009-10-28 | Pharmaceutical compositions containing diacerein |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012506911A JP2012506911A (ja) | 2012-03-22 |
| JP2012506911A5 true JP2012506911A5 (enExample) | 2012-12-06 |
| JP5642691B2 JP5642691B2 (ja) | 2014-12-17 |
Family
ID=42117735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011534697A Expired - Fee Related JP5642691B2 (ja) | 2008-10-28 | 2009-10-28 | ジアセレインを含有する医薬組成物 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20100104651A1 (enExample) |
| EP (1) | EP2349289B1 (enExample) |
| JP (1) | JP5642691B2 (enExample) |
| KR (1) | KR101718347B1 (enExample) |
| CN (1) | CN102202673B (enExample) |
| AR (1) | AR073918A1 (enExample) |
| AU (1) | AU2009308958B2 (enExample) |
| BR (1) | BRPI0920255A2 (enExample) |
| CA (1) | CA2741846C (enExample) |
| ES (1) | ES2585904T3 (enExample) |
| IL (1) | IL212483A (enExample) |
| MX (1) | MX2011004395A (enExample) |
| NZ (1) | NZ592376A (enExample) |
| PA (1) | PA8846801A1 (enExample) |
| RU (1) | RU2542461C2 (enExample) |
| SA (1) | SA109300644B1 (enExample) |
| TW (1) | TWI473610B (enExample) |
| UY (1) | UY32204A (enExample) |
| WO (1) | WO2010051296A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2555618B1 (en) * | 2010-04-08 | 2015-12-30 | TWI Biotechnology, Inc. | Methods of using diacerein as an adjunctive therapy for diabetes |
| CN101822660B (zh) * | 2010-05-13 | 2013-07-10 | 中国人民解放军肾脏病研究所 | 大黄酸类化合物或其盐在制备预防和治疗胰岛β细胞功能衰退药物中的应用 |
| WO2012125359A1 (en) * | 2011-03-11 | 2012-09-20 | Twi Biotechnology, Inc. | Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia |
| CN102743370B (zh) * | 2011-06-27 | 2013-05-15 | 王子厚 | 双醋瑞因的用途 |
| CN103930132A (zh) * | 2011-09-27 | 2014-07-16 | 拜奥迈德瓦利探索有限公司 | 治疗胶质瘤的组合物和方法 |
| US20140336148A1 (en) * | 2011-12-27 | 2014-11-13 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Combinations of diacerein and non-steroidal inflammation drugs |
| US20150004229A1 (en) * | 2011-12-27 | 2015-01-01 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Combined pharmaceutical formulation containing diacerein |
| CN102871982B (zh) * | 2012-10-16 | 2014-09-10 | 中国科学院上海药物研究所 | 一种药物渗透泵制剂 |
| US11198724B2 (en) | 2013-03-14 | 2021-12-14 | The Regents Of The University Of Michigan | Treatment of staphylococcal disorders |
| JP2018513203A (ja) * | 2015-04-20 | 2018-05-24 | ティダブリューアイ・バイオテクノロジー・インコーポレイテッドＴＷＩ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． | ジアセレインを含有する製剤及びそれを用いて尿酸の血中濃度を低下させる方法 |
| EP3316879A4 (en) * | 2015-07-01 | 2019-01-23 | TWI Biotechnology, Inc. | TOPICAL DIACEREIN OR RHEIN FORMULATIONS AND USES THEREOF |
| US10512625B2 (en) * | 2015-07-01 | 2019-12-24 | Twi Biotechnology, Inc. | Diacerein or rhein topical formulations and uses thereof |
| US10154984B2 (en) * | 2015-07-01 | 2018-12-18 | Twi Biotechnology, Inc. | Diacerein or Rhein topical formulations and uses thereof |
| CN108349867B (zh) * | 2015-08-17 | 2021-03-09 | 安成生物科技股份有限公司 | 用于抑制asc的表达、nlrp3的表达和/或nlrp3炎性复合体的形成的双醋瑞因或其类似物 |
| AU2018210771B2 (en) * | 2017-01-18 | 2020-04-02 | Tairx, Inc. | Compositions for use in treating inflammatory bowel diseases and intestinal colitis |
| US10675260B2 (en) * | 2017-01-19 | 2020-06-09 | Twi Biotechnology, Inc. | Methods and pharmaceutical compositions for preventing or treating immunoinflammatory dermal disorders |
| ES2938609T3 (es) * | 2017-09-20 | 2023-04-13 | Tillotts Pharma Ag | Preparación de formas farmacéuticas sólidas que comprenden anticuerpos mediante estratificación de solución/suspensión |
| CN107929264B (zh) * | 2017-12-04 | 2020-04-24 | 广东药科大学 | 双醋瑞因缓释微球及其制备方法 |
| KR102075724B1 (ko) * | 2018-09-14 | 2020-02-10 | 한국원자력의학원 | 디아세레인을 유효성분으로 포함하는 항체의 종양 침투력 증진용 조성물 및 이의 용도 |
| IL283127B1 (en) | 2018-11-14 | 2026-02-01 | Smilebiotek Zhuhai Ltd | Animal-based models, scanning methods, and methods of treating intraocular diseases or disorders |
| CN110787157A (zh) * | 2019-11-27 | 2020-02-14 | 中南民族大学 | 双醋瑞因在用于舒张预收缩的气管平滑肌及治疗哮喘中的应用 |
| CN113440503B (zh) * | 2021-07-02 | 2022-03-18 | 温州医科大学附属口腔医院 | 超长效可控缓释介孔-透明质酸杂化靶向抗菌纳米材料及其制备方法、用途 |
| CN115227664A (zh) * | 2022-06-27 | 2022-10-25 | 苏州中化药品工业有限公司 | 一种双醋瑞因胶囊及其制备方法与应用 |
| WO2024200722A1 (en) * | 2023-03-28 | 2024-10-03 | Tillotts Pharma Ag | Solid oral dosage form comprising antibodies for sustained release in the lower gastrointestinal tract |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA761627B (en) * | 1976-03-16 | 1978-01-25 | C Friedmann | Improvements in or relating to the treatment of arthritis |
| US5225192A (en) * | 1988-10-17 | 1993-07-06 | Vectorpharma International S.P.A. | Poorly soluble medicaments supported on polymer substances in a form suitable for increasing their dissolving rate |
| US5569469A (en) * | 1984-10-16 | 1996-10-29 | Vectorpharma International, S.P.A. | Poorly soluble medicaments supported on polymer substances in a form suitable for increasing their dissolving rate |
| IT1197316B (it) * | 1986-10-01 | 1988-11-30 | Proter Spa | Formulazione galenica ad uso orale di derivati della reina a lento rilascio per impiego terapeutico |
| IT1230566B (it) * | 1988-10-17 | 1991-10-28 | Vectorpharma Int | Farmaci poco solubili supportati su sostanze polimeriche in forma atta all'aumento della velocita' di dissoluzione |
| IT1241417B (it) * | 1990-03-06 | 1994-01-14 | Vectorpharma Int | Composizioni terapeutiche a rilascio controllato di farmaci supportatisu polimeri reticolati e rivestiti con film polimerici,e loro processodi preparazione |
| IT1255522B (it) * | 1992-09-24 | 1995-11-09 | Ubaldo Conte | Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita' |
| US5840881A (en) * | 1992-11-27 | 1998-11-24 | Takeda Chemical Industries, Ltd. | Composition containing a water-insoluble or slightly water-soluble compound with enhanced water-solubility |
| ATE183641T1 (de) * | 1992-12-23 | 1999-09-15 | Saitec Srl | Verfahren zur herstellung von arzneiformen und kontrollierte freigabe und die soerhaltenen arzneiformen |
| FR2757397B1 (fr) * | 1996-12-23 | 1999-03-05 | Mazal Pharma | Composition pharmaceutique a base de rheine ou de diacerheine a biodisponibilite amelioree |
| US6197818B1 (en) * | 1998-09-01 | 2001-03-06 | Nanjing General Hospital Of Nanjing Command, Pla | Drug for treating diabetic nephrosis |
| IL160310A0 (en) * | 2001-08-25 | 2004-07-25 | Arakis Ltd | The use of anthroquinones in the treatment of kidney disease |
| FR2842738B1 (fr) * | 2002-07-23 | 2006-02-10 | Negma Lerads | Utilisation d'une rheine pour la preparation d'un medicament pour le traitement de l'inflammation chronique, la prevention et le traitement du rejet des transplantations d'organes et de tissus |
| AU2003304236A1 (en) * | 2002-08-30 | 2005-01-13 | Pharmacia Corporation | Pharmaceutical solid dosage forms exhibiting reproductible drug release profile |
| WO2004066981A1 (en) * | 2003-01-29 | 2004-08-12 | Sun Pharmaceutical Industries Limited | Oral controlled release pharmaceutical composition containing metaxalone as active agent |
| MXPA04009698A (es) * | 2004-10-04 | 2006-04-05 | Maria Elena Garcia Armenta | Formulaciones farmaceuticas solidas conteniendo diacereina y meloxicam. |
| CN1748675A (zh) * | 2005-07-11 | 2006-03-22 | 丛晓东 | 大黄酸类化合物的复合物及制备方法与治疗糖尿病的应用 |
| US8158152B2 (en) * | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| CN100475201C (zh) * | 2007-03-19 | 2009-04-08 | 上海慈瑞医药科技有限公司 | 二乙酰大黄酸缓释片的制备方法 |
| CA2926610A1 (en) * | 2007-09-27 | 2009-04-02 | Wockhardt Research Centre | Pharmaceutical compositions of rhein or diacerein |
| WO2009048940A2 (en) * | 2007-10-08 | 2009-04-16 | Dr. Reddy's Laboratories Ltd. | Diacerein pharmaceutical formulations |
-
2009
- 2009-10-07 TW TW98134006A patent/TWI473610B/zh not_active IP Right Cessation
- 2009-10-22 AR ARP090104059A patent/AR073918A1/es not_active Application Discontinuation
- 2009-10-27 SA SA109300644A patent/SA109300644B1/ar unknown
- 2009-10-28 UY UY0001032204A patent/UY32204A/es not_active Application Discontinuation
- 2009-10-28 US US12/607,251 patent/US20100104651A1/en not_active Abandoned
- 2009-10-28 BR BRPI0920255A patent/BRPI0920255A2/pt not_active IP Right Cessation
- 2009-10-28 CN CN2009801431098A patent/CN102202673B/zh not_active Expired - Fee Related
- 2009-10-28 KR KR1020117012172A patent/KR101718347B1/ko not_active Expired - Fee Related
- 2009-10-28 RU RU2011121609/15A patent/RU2542461C2/ru not_active IP Right Cessation
- 2009-10-28 CA CA2741846A patent/CA2741846C/en not_active Expired - Fee Related
- 2009-10-28 PA PA20098846801A patent/PA8846801A1/es unknown
- 2009-10-28 WO PCT/US2009/062302 patent/WO2010051296A1/en not_active Ceased
- 2009-10-28 MX MX2011004395A patent/MX2011004395A/es active IP Right Grant
- 2009-10-28 EP EP09824084.9A patent/EP2349289B1/en not_active Not-in-force
- 2009-10-28 NZ NZ592376A patent/NZ592376A/xx not_active IP Right Cessation
- 2009-10-28 JP JP2011534697A patent/JP5642691B2/ja not_active Expired - Fee Related
- 2009-10-28 ES ES09824084.9T patent/ES2585904T3/es active Active
- 2009-10-28 AU AU2009308958A patent/AU2009308958B2/en not_active Ceased
-
2011
- 2011-04-26 IL IL212483A patent/IL212483A/en active IP Right Grant
-
2013
- 2013-02-15 US US13/768,844 patent/US20130156857A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2011121609A (ru) | Фармацевтические композиции, содержащие диацереин | |
| US9446032B2 (en) | Methods for treating cardiovascular disorders | |
| KR20110103928A (ko) | 안지오텐신-ⅱ-수용체 차단제를 포함하는 약제학적 제제 | |
| KR20210016436A (ko) | 글루코키나제 활성화제 및 ppar 수용체 활성화제를 함유하는 약제학적 병용물, 조성물, 및 병용 제제, 및 이의 제조 방법 및 용도 | |
| TW200418453A (en) | Modified release pharmaceutical compositions | |
| KR101156054B1 (ko) | 안정한 에페리손 함유 서방성 의약조성물 | |
| AU2012303683A1 (en) | Methods for treating cardiovascular disorders | |
| CA2642851A1 (en) | Low flush niacin formulation | |
| US20030147957A1 (en) | Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester and a decarboxylase inhibitor in a controlled release core | |
| TW201035089A (en) | Pharmaceutical composition | |
| CN106983726B (zh) | 阿齐沙坦片及其制备方法 | |
| CN111818927A (zh) | 用于治疗炎性皮肤疾病的米诺环素 | |
| WO2022225489A1 (en) | A bilayer tablet formulation comprising amorphous dapagliflozin and metformin | |
| CN101642443B (zh) | 单硝酸异山梨酯渗透泵型控释制剂及其制备方法 | |
| WO2014096982A1 (en) | Stable pharmaceutical compositions of saxagliptin or salts thereof | |
| TW201201800A (en) | A pharmaceutical controlled release composition of losartan | |
| RU2014146936A (ru) | Композиции с немедленным высвобождением лекарственного средства | |
| CN102058591A (zh) | 一种左旋氨氯地平和替米沙坦的复方制剂 | |
| CA2946158A1 (en) | Pharmaceutical composition with anti-inflammatory agents and production process | |
| WO2023136797A2 (en) | A bilayer tablet composition comprising amorphous dapagliflozin and metformin | |
| AU2020411858A1 (en) | Drug for preventing dialysis shift or renal death | |
| FI4032530T3 (fi) | Pidennetysti vapautuva furatsidiinikoostumus | |
| CN102784143A (zh) | 一种含美托洛尔和非洛地平的单层渗透泵控释制剂 | |
| WO2014007777A1 (en) | Combined capsule formulations of nsaids | |
| WO2014096983A1 (en) | Stable pharmaceutical compositions of saxagliptin or salts thereof |